Shots:
- Abbott has received Health Canada’s approval for the Esprit BTK Everolimus Eluting Resorbable Scaffold System to treat people with chronic limb-threatening ischemia (CLTI) below the knee (BTK)
- Esprit was evaluated in the LIFE-BTK trial against balloon angioplasty, which showed improved patient outcomes, with 48% fewer repeat procedures over the study period. Data was highlighted at VIVA’24
- The Esprit BTK System is a resorbable scaffold that is implanted via a minimally invasive catheter procedure to support below-the-knee vessels after blockage clearance for ~3yrs., then gradually dissolves as the vessel heals
Ref: Newswire.CA | Image: Abbott | Press Release
Related News:- Abbott’s Navitor TAVI System Receives European CE Mark for Aortic Stenosis in Patients at Low or Intermediate-Risk for Surgery
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
